1) Dias MF, Joo K, Kemp JA, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog Retin Eye Res 2018;63:107-31.
3) Na KH, Kim HJ, Kim KH, et al. Prevalence, age at diagnosis, mortality, and cause of death in retinitis pigmentosa in Korea‐a nationwide population‐based study. Am J Ophthalmol 2017;176:157-65.
4) Pagon RA. Retinitis pigmentosa. Surv Ophthalmol 1988;33:137-77.
5) Verbakel SK, van Huet RAC, Boon CJF, et al. Non‐syndromic retinitis pigmentosa. Prog Retin Eye Res 2018;66:157-86.
7) Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-90.
8) Lupo S, Grenga PL, Vingolo EM. Fourier‐domain optical coherence tomography and microperimetry findings in retinitis pigmentosa. Am J Ophthalmol 2011;151:106-11.
10) Sandberg MA, Gaudio AR, Berson EL. Disease course of patients with pericentral retinitis pigmentosa. Am J Ophthalmol 2005;140:100-6.
11) Herse P. Retinitis pigmentosa: visual function and multidisciplinary management. Clin Exp Optom 2005;88:335-50.
12) Choi YJ, Shin MH, Han YS, et al. Pars plana vitrectomy for cystoid macular edema in a retinitis pigmentosa patient. J Korean Ophthalmol Soc 2018;59:790-6.
13) Jang SY, Lim SH, Ohn YH. Multifocal electroretinography in retinitis pigmentosa with non‐recordable full‐field electroretinography. J Korean Ophthalmol Soc 2009;50:1817-23.
15) Yoo SH, Sun HJ, Lee SJ, Ohn YH. Unilateral retinitis pigmentosa: a case series and literature review. J Korean Ophthalmol Soc 2015;56:559-66.
17) Milam AH, Li ZY, Fariss RN. Histopathology of the human retina in retinitis pigmentosa. Prog Retin Eye Res 1998;17:175-205.
18) Wojtkowski M, Bajraszewski T, Gorczyńska I, et al. Ophthalmic imaging by spectral optical coherence tomography. Am J Ophthalmol 2004;138:412-9.
21) Fujiwara K, Ikeda Y, Murakami Y, et al. Risk factors for posterior subcapsular cataract in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2017;58:2534-7.
22) Joy A, Al‐Ghoul KJ. Basal membrane complex architecture is disrupted during posterior subcapsular cataract formation in Royal College of Surgeons rats. Mol Vis 2014;20:1777-95.
23) Yoshida N, Ikeda Y, Notomi S, et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2013;120:100-5.
24) Liew G, Strong S, Bradley P, et al. Prevalence of cystoid macular oedema, epiretinal membrane and cataract in retinitis pigmentosa. Br J Ophthalmol 2019;103:1163-6.
25) Hajali M, Fishman GA. The prevalence of cystoid macular oedema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination. Eye (Lond) 2009;23:915-9.
26) Strong S, Liew G, Michaelides M. Retinitis pigmentosa‐associated cystoid macular oedema: pathogenesis and avenues of intervention. Br J Ophthalmol 2017;101:31-7.
27) Park UC, Park JH, Ma DJ, et al. A randomized paired‐eye trial of intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa. Retina 2020;40:1359-66.
28) Piazza L, Fishman GA, Farber M, et al. Visual acuity loss in patients with Usher's syndrome. Arch Ophthalmol 1986;104:1336-9.
29) Han SB, Kim SJ, Kim JH, et al. The clinical manifestations of Usher syndrome in Korea. J Korean Ophthalmol Soc 2007;48:950-6.
30) Stavrou P, Good PA, Broadhurst EJ, et al. ERG and EOG abnormalities in carriers of X‐linked retinitis pigmentosa. Eye (Lond) 1996;10(Pt 5):581-9.
31) Arden GB, Wolf JE. The electro‐oculographic responses to alcohol and light in a series of patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci 2000;41:2730-4.
34) Kim C, Kim KJ, Bok J, et al. Microarray‐based mutation detection and phenotypic characterization in Korean patients with retinitis pigmentosa. Mol Vis 2012;18:2398-410.